A Phase 3 interventional study of Zonisamide and Bupropion in Smoking Cessation, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-13.
Sponsored by Rose Research Center, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing bupropion in Smoking Cessation — 4 open to participants now, 4 under way, 2 of them phase 3. Bupropion · Smoking Cessation.
Among the 48 studies testing bupropion in Smoking Cessation, this one is the 40th largest by enrollment, is one of 2 that started in 2020, is one of 14 in phase 3, and was the 39th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →4 of the 48 studies testing bupropion in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
University of Kansas Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–65
Medical University of South Carolina · Sites in United States
Ages 18–65
By country, each count listing its studies:
Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 15 · Phase 4 17
First in 1998; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 162 across the 48 interventional studies. Of the 42 that completed or were terminated, 22 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 48 have an industry lead sponsor. The 10 most frequent:
Rose Research Center, LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
10 studies in Smoking Cessation by Rose Research Center, LLC: none open now, none under way, none of them phase 3. Of 9 finished, 4 (44%) have results posted.
Among the 10 studies in Smoking Cessation by Rose Research Center, LLC, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 3, and was the 4th registered.
Rose Research Center, LLC’s Smoking Cessation studies by the year they started, since 2019.
1 of the studies testing bupropion in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05732272Phase 3University of Kansas Medical CenterImproving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 48 studies testing bupropion in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Rose Research Center, LLC’s 10 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline data on use of combustible cigarettes. Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in addition to continued use of the G6. At each visit, participants will receive enough zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6 and combination zonisamide and bupropion use will continue until the participant returns for the End-of-Study visit (V7).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of any of these products in the past 30 days:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.
Drug: Zonisamide · Drug: Bupropion · Other: Halo G6 e-cigarette
Zonisamide (100 mg/daily) for 12 weeks.
Also known as: zonegran
Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
Also known as: wellbutrin, Zyban
G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
Also known as: e-cigarette
Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes
Defined as self-report of no cigarette smoking (not even a puff), confirmed by an expired air CO reading of less than 5 ppm.
Time frame: Weeks 8-11 post-quit date (weeks 10-13 post baseline)
Point Abstinence From Combustible Cigarettes
Assessed by self-report utilizing an automated SMS messaging system.
Time frame: Six months post switch day (approximately 6 months post baseline)
Change in Rewarding Effects of Smoking Combustible Cigarettes
Characterize changes in the two primary scales of the Cigarette Evaluation Questionnaire (mCEQ), assessing smoking satisfaction and psychological reward, compared between cigarettes smoked after meals versus all others smoked during the day, examining how this difference changes after zonisamide/bupropion usage. The mCEQ uses a 7-point scale (0=Not at all; 1=Very little; 2=A little; 3=Moderately; 4=A lot, 5=Quite a lot; 6=Extremely) to measure the following subscales: Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract Sensations, Craving Reduction, Aversion.
Time frame: First week compared to after start of study drugs (Weeks 2-13 post baseline)
| Milestone | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Started | 26 |
| Completed | 24 |
| Not completed | 2 |
| Milestone | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Started | 24 |
| Completed | 23 |
| Not completed | 1 |
Defined as self-report of no cigarette smoking (not even a puff), confirmed by an expired air CO reading of less than 5 ppm.
| Participants | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes | 8 |
Assessed by self-report utilizing an automated SMS messaging system.
| Participants | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Point Abstinence From Combustible Cigarettes | 15 |
Characterize changes in the two primary scales of the Cigarette Evaluation Questionnaire (mCEQ), assessing smoking satisfaction and psychological reward, compared between cigarettes smoked after meals versus all others smoked during the day, examining how this difference changes after zonisamide/bupropion usage. The mCEQ uses a 7-point scale (0=Not at all; 1=Very little; 2=A little; 3=Moderately; 4=A lot, 5=Quite a lot; 6=Extremely) to measure the following subscales: Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract Sensations, Craving Reduction, Aversion.
| score on a scale | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| CEQ Satisfaction Scale | 0 ± 1.2 |
| CEQ Psych Reward Scale | 0.2 ± 1.1 |
Collected over During 13 week study period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Zonisamide and Bupropion With E-cigarette | 0/24 (0%) | 0/24 (0%) | 22/24 (91.7%) |
| Event | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| ConstipationGastrointestinal disorders | 5/24 |
| HeadacheNervous system disorders | 5/24 |
| Throat irritationGastrointestinal disorders | 4/24 |
| NauseaGastrointestinal disorders | 4/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/24 |
| TinnitusNervous system disorders | 2/24 |
| Dry mouthGastrointestinal disorders | 2/24 |
| DizzinessNervous system disorders | 2/24 |
| Aversion to cigarettesNervous system disorders | 2/24 |
| AnxietyNervous system disorders | 2/24 |
Two participants were enrolled into the study but discontinued prior to taken any study drug so analysis is based on the 24 participants who started the study drug.
| Age, Categorical(Participants) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 26 |
| >=65 years | 0 |
| Age, Continuous(years) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Mean | 45.1 ± 9.75 |
| Sex: Female, Male(Participants) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Female | 8 |
| Male | 18 |
| Ethnicity (NIH/OMB)(Participants) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 25 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 18 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| United States | 26 |
| Cigarettes smoked per day (CPD)(Cigs smoked per day) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Mean | 21.2 ± 6.64 |
| FTND -- The Fagerström Test for Nicotine Dependence Score(units on a scale) | Combination Zonisamide and Bupropion With E-cigarette |
|---|---|
| Mean | 6.1 ± 1.82 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2020 to primary completion in Jun 2021, 12 months.
Results were first posted in Mar 2022, 9 months after primary completion.
Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zonisamide · Bupropion
Rose Research Center, LLC